Deep Sequencing of Target Linkage Assay-Identified Regions in Familial Breast Cancer: Methods, Analysis Pipeline and Troubleshooting

Juan Manuel Rosa-Rosa¹, Francisco Javier Gracia-Aznárez¹, Emily Hodges², Guillermo Pita³, Michelle Rooks², Zhenyu Xuan⁴, Arindam Bhattacharjee⁵, Leonardo Brizuela⁵, José M. Silva⁶, Gregory J. Hannon², Javier Benitez¹³.

¹ Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, ² Howard Hughes Medical Institute, Cold Spring Harbor Laboratory (CSHL), Cold Spring Harbor, New York, United States of America, ³ Genotyping Unit (CEGEN), Spanish National Cancer Research Centre, Madrid, Spain, ⁴ Department of Molecular and Cell Biology, The University of Texas, Richardson, Texas, United States of America, ⁵ Agilent Technologies, Inc., Santa Clara, California, United States of America, ⁶ Irving Cancer Research Center, New York, New York, United States of America

Abstract

Background: The classical candidate-gene approach has failed to identify novel breast cancer susceptibility genes. Nowadays, massive parallel sequencing technology allows the development of studies unaffordable a few years ago. However, analysis protocols are not yet sufficiently developed to extract all information from the huge amount of data obtained.

Methodology/Principal Findings: In this study, we performed high throughput sequencing in two regions located on chromosomes 3 and 6, recently identified by linkage studies by our group as candidate regions for harbouring breast cancer susceptibility genes. In order to enrich for the coding regions of all described genes located in both candidate regions, a hybrid-selection method on tiling microarrays was performed.

Conclusions/Significance: We developed an analysis pipeline based on SOAP aligner to identify candidate variants with a high real positive confirmation rate (0.89), with which we identified eight variants considered candidates for functional studies. The results suggest that the present strategy might be a valid second step for identifying high penetrance genes.

Introduction

Breast cancer (BC [MIM #114480]) is the most frequent malignancy among women, with approximately one million new cases per year around the world [1]. About five percent of all BC cases are considered to be hereditary, and mutations in either the BRCA1 [MIM +113705] or the BRCA2 [MIM +600185] gene account for 25–30% of these cases [2]. Thus, about 70% of BC families remain unexplained, and are known as non-BRCA1/2 families [3]. In this regard, several linkage studies have been performed during the last years on familial BC, and many candidate regions that may contain BC susceptibility genes have been described. However, mutational screenings in linkage assay-identified regions using the classical candidate-gene approach did not identify any clear pathogenic variants [4,5,6]. Therefore, new strategies seem to be necessary.

Massive parallel sequencing technology allows nowadays the development of studies unachievable a few years ago. Despite the fact that the advantages of this technology were evidenced in each of the published studies based on it, the analysis of all data generated by this process remains a hard task to face. The first step in the regular analysis protocol is based on the alignment of millions of short sequences obtained from each run. For that reason, during the past years many computer tools have been developed to improve the accuracy of this process [7,8,9]. One of the main obstacles is the specificity in the analysis of the data to obtain the output required by any given study. For example, the identification of novel variants, chromosomal translocations, or transcription factor target sites are some of the aims of the many studies that can be performed using high throughput sequencing technologies, and each of them would require a specific analysis pipeline.

A major success in the use of this technology was the re-sequencing of the whole human genome, published in several studies in the past years [10,11,12,13,14]. The results showed a higher complexity level of the human genome, with the
appearance of many new variants, short length insertions and deletions and, even, small inversions. However, the amount of time required for re-sequencing large genomes and its high economic cost make it impractical as a common laboratory technique. For that reason, the search for specific sequence-enrichment protocols applicable to massive parallel sequencing has been an important goal during these years. One of the approaches developed [15] and improved [16] to obtain this specific enrichment is the technique of selective exon-capture or hybrid selection, based on high-density tiling DNA microarrays.

In a previous study, we performed a SNP-based linkage analysis in 41 non-BRCA1/2 families and obtained several candidate regions for containing BC susceptibility genes [17]. The large size of the candidate regions and the high number of genes described within them, led us to couple linkage analysis with high-throughput sequencing-based mutational screening as a new strategy for variation detection. In the present study, we used hybrid selection of discrete genomic intervals on custom-designed microarrays as an exon-specific enrichment of all the genes located within two complete candidate regions on chromosomes 3 and 6, that presented a suggestive linkage LOD score (LOD>2.2). We also describe the complex analysis pipeline based on SOAP aligner, developed to analyse all the data obtained, and present eight variants that are candidates for playing a role in the development of familial BC.

Results

Regions and capture
We performed a complete mutational screening via single-end massive parallel sequencing technology on the 128 known genes located on two different chromosomal regions, previously described as candidates for containing a breast cancer susceptibility gene [17]. The first region is located on 3q25, extends over 10.8 Mb (from 160,964 to 171,786 Kb), and contains 69 known genes; the second region is located on 6q24 and spans 6.5 Mb (from 146,078 to 152,513 Kb), containing 59 known genes. To selectively sequence the coding region of these genes, we used hybrid selection on tiling microarrays [16], which was validated via qPCR (data not shown).

Reads, coverage and depth
DNA samples from 20 affected individuals, belonging to 9 different non-BRCA1/2 families, and 4 healthy unrelated individuals from the control population were used for the analysis process. More than 102 million reads were obtained from the affected individuals and almost 22.4 million reads were obtained from the control individuals (see Table 1). The average number of reads per affected individual was 5.14 million, and this number was increased to 5.21 million when control individuals were taken into account. We used SOAP v1.0 to align our data set, obtaining an average of 91.38% aligned sequences against the whole genome with ≤2 mismatches. Among these, an average of 39.99% matched our candidate coding regions. Thus, since the total number of base pairs covered by the tiling array is 0.014% of the genome length (434,039 bp), the average enrichment was approximately 2.85 thousand times, calculated as the percentage of the sequences aligned to the genome that successfully matched to the candidate regions (39.99) divided by the percentage of the genome length that candidate regions represent (0.014).

We calculated the coverage (number of bases covered after the alignment) per individual and obtained an average of 98.25% of candidate bases covered for the affected and the control individuals (Table 1). We did not observe significant coverage differences between the candidate coding regions located on chromosomes 3 and 6. Importantly, a lack of correlation between the coverage and the total number of sequences was observed (r² = 0.013, Figure S1A). However, this lack of correlation turned into a logarithmic trend when the number of sequences aligned to the candidate coding regions was used (r² = 0.69, Figure S1B).

In order to know the power to confidently detect possible causal variants, we calculated the global depth (number of sequences that cover a single base) for every base along the candidate coding regions per individual. As expected, a strong correlation (r² = 0.96) was found between the global depth and the number of reads aligned to the candidate coding regions (Figure S1C). Taking into account only those bases that presented coverage (depth >0), from both affected and controls individuals, the mean and the median of the depth were 37 and 34 respectively, showing a strong correlation between them (r² = 0.98, Figure S1D).

Data quality control

a) Coverage homogeneity. We calculated the mean and the median of the depth for stretches of 15 bases along the candidate regions, and obtained the log-ratio of the median between each affected individual and the control pool. The mean log-ratio for the global data was −0.06 with a standard deviation of 0.55 (Table 2), showing a homogeneous distribution of the coverage between affected and control individuals. We calculated the upper and lower threshold for each individual (Table 2) and we identified several regions where the coverage differed between the affected individuals and the control pool (data not shown), most of them flanking the candidate coding regions (which are usually low coverage regions). In addition, the strong correlation (r² = 0.99, Figure S1E) between the median and the mean of the coverage for these regions in the dataset supported that these differences in coverage are not due to extreme values within the same coding region but are due to chance, ruling out potential problems in the capture step.

b) Score. Genotype calling accuracy was demonstrated elsewhere (>90% of the known SNPs) by using a HapMap sample in the exon-capture report [16]. In order to test the suitability of our analysis pipeline when looking for unknown polymorphisms, we used the candidate SNPs from a single family obtained using different Depth Score (DS, see Material and Methods) thresholds for both the affected samples and the control pool data (Table 3). We observed that from DS = 50 onwards for the samples, the DS threshold used for the control pool data had no effect on the number of candidate SNPs, highlighting the specificity of our DS. In order to be as conservative as possible, we considered that the best False Positive/False Negative (FP/FN) relationship was for a DS >50 for samples and a DS >14 for the control pool. Additionally, we performed an analysis using MAQ software in a subgroup of families and we observed that there was no correlation between MAQ variant score and Sanger confirmation (Table 4). These results demonstrated the higher accuracy of our analysis methodology compared to the algorithm used by MAQ.

Variant identification
We included a first filter (see Material and Methods) in our SOAP-based SNP-caller to discard the maximum amount of false positives, obtaining 99% of SNP variants discarded (Figure 1). We selected only those variants located on the chromosome of interest for each individual, resulting in an average of 71 SNPs per individual (Table 5). Subsequent filters (discarding homozygous variants, comparing to controls and comparing within members of
the same family) discarded almost 80% of the remaining SNPs. Then, we used a newly developed Perl script to differentiate between described and previously undescribed SNPs and also to obtain the functional consequences for each undescribed SNP, resulting in 5 undescribed variants per family on average. Since we observed that one variant could have consequences for more than one transcript/gene, subsequent filtering was performed using the consequences of the variants instead of the variants themselves. Next, we discarded intronic consequences and continued the analysis with exonic consequences only (an average of 23% of the original number of consequences). After that, each of the remaining SNPs showed only the consequences of one variant could have consequences for more than one transcript/gene, remaining three indels were homozygous with a global depth = 1. Thus, no putative truncating indel was found in our individual dataset. In order to rule out the possibility that a putative causal indel could be found in one member of a family but not in the other members, we checked the consequences for the remaining indels after the comparison to the control pool data for all 20 individuals members, we checked the consequences for the remaining indels could be found in one member of a family but not in the other members, we checked the consequences for the remaining indels were located in intronic regions, two were located in 3' UTR regions, and the remaining three indels were homoyzous with a maximum length allowed for an indel variant), an average of only 1.15 indels per individual were identified, and this number decreased to 0.50 after comparison to the control pool of data. Moreover, no indel was found to segregate in our family dataset. In order to rule out the possibility that a putative causal indel could be found in one member of a family but not in the other members, we checked the consequences for the remaining indels after the comparison to the control pool data for all 20 individuals from the 9 non-BRCA1/2 families. We observed a total of 8 undescribed indel variants for the 20 individuals. Three of them could be found in one member of a family but not in the other members, we checked the consequences for the remaining indels were located in intronic regions, two were located in 3' UTR regions, and the remaining three indels were homoyzous with a global depth = 1. Thus, no putative truncating indel was found in our individual dataset (Table S1).

### Discussion

**High-throughput sequencing**

The classical candidate-gene approach turned out to be a low-efficiency tool with regard to cost and time when used for the identification of causal genes in genetic diseases, especially when there

---

**Table 1. Summary of high throughput sequencing data.**

| Chromosome | Family | Individual | Number of sequences | Depth       | Coverage in % | Mean | Median |
|------------|--------|------------|---------------------|-------------|---------------|------|--------|
| 3          | 27     | 075722     | 3,123,937           | 2,956,483 (94.64) | 1,186,611 (40.14) | 98.04 | 26 25  |
|            |        | 075723     | 4,922,157           | 4,538,392 (92.20)  | 1,518,625 (33.46) | 98.43 | 29 29  |
|            |        | 075724     | 4,183,568           | 3,954,837 (94.53)  | 1,515,614 (38.32) | 97.89 | 28 28  |
| 60         | 06-240 | 075725     | 2,952,969           | 2,839,271 (96.15)  | 1,168,679 (41.16) | 97.11 | 24 24  |
|            | 96-652 | 5,934,453  | 4,737,175           | 1,767,157 (79.82)  | 1,670,157 (35.26) | 98.15 | 28 24  |

The number of sequences and the depth values are shown for a total of 20 individuals from 9 non-BRCA1/2 families and 4 individuals from the control population (Control pool).

*Chromosome in which linkage signal was found for each of the families.

**with respect to the total number of sequences, ** with respect to the numbers of sequences aligned to the whole genome.

Summary of high throughput sequencing data.

| Chromosome | Family | Individual | Number of sequences | Depth       | Coverage in % | Mean | Median |
|------------|--------|------------|---------------------|-------------|---------------|------|--------|
| 3          | 27     | 075722     | 3,123,937           | 2,956,483 (94.64) | 1,186,611 (40.14) | 98.04 | 26 25  |
|            |        | 075723     | 4,922,157           | 4,538,392 (92.20)  | 1,518,625 (33.46) | 98.43 | 29 29  |
|            |        | 075724     | 4,183,568           | 3,954,837 (94.53)  | 1,515,614 (38.32) | 97.89 | 28 28  |
| 60         | 06-240 | 075725     | 2,952,969           | 2,839,271 (96.15)  | 1,168,679 (41.16) | 97.11 | 24 24  |
|            | 96-652 | 5,934,453  | 4,737,175           | 1,767,157 (79.82)  | 1,670,157 (35.26) | 98.15 | 28 24  |

The number of sequences and the depth values are shown for a total of 20 individuals from 9 non-BRCA1/2 families and 4 individuals from the control population (Control pool).

*Chromosome in which linkage signal was found for each of the families.

**with respect to the total number of sequences, ** with respect to the numbers of sequences aligned to the whole genome.

doi:10.1371/journal.pone.0009976.t001

Regarding indel variants, we followed the same analysis pipeline as with SNP variants. Even though 12 bp gaps were allowed (maximum length allowed for an indel variant), an average of only 1.15 indels per individual were identified, and this number decreased to 0.50 after comparison to the control pool of data. Moreover, no indel was found to segregate in our family dataset. In order to rule out the possibility that a putative causal indel could be found in one member of a family but not in the other members, we checked the consequences for the remaining indels after the comparison to the control pool data for all 20 individuals from the 9 non-BRCA1/2 families. We observed a total of 8 undescribed indel variants for the 20 individuals. Three of them were located in intronic regions, two were located in 3' UTR regions, and the remaining three indels were homoyzous with a global depth = 1. Thus, no putative truncating indel was found in our individual dataset (Table S1).
In order to evaluate the quality of the coverage within the candidate coding region, we calculated an index value [16], see Table 2. We observed that the threshold used for the control pool did not affect the total number of variants identified when using a DS threshold of 50 or higher for the cases. Taking into account the false positive rates (FPR) and false negative rates (FNR), and in order to be as conservative as possible, we finally chose a DS threshold of 50 for cases and a DS threshold of 14 for the control pool data.

### Table 2. Depth Score threshold optimization assay.

| Chr | Global | DS_Control Pool | Candidate SNPs before homology | Candidate SNPs after homology | Confirmed by Sanger | FPR | FNR |
|-----|--------|-----------------|--------------------------------|------------------------------|--------------------|-----|-----|
| 9   | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 10  | 0      | 14              | 15791                          | 15880                        | 60                 | 0   | 0   |
| 20  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 30  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 40  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 50  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 60  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 70  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 80  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 90  | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |
| 100 | 0      | 14              | 15791                          | 15880                        | 33                 | 0   | 0   |

The filtering results for various DS scores in a sample family (Family 990) are shown below. We observed that the threshold used for the control pool did not affect the total number of variants identified when using a DS threshold of 50 or higher for the cases. Taking into account the false positive rates (FPR) and false negative rates (FNR), and in order to be as conservative as possible, we finally chose a DS threshold of 50 for cases and a DS threshold of 14 for the control pool data.

doi:10.1371/journal.pone.0009976.t002
Mutational screening

In order to identify de novo mutations, we consider that the best option is to maintain those sequences that match equally to more than one location, even though it could be a source of alignment errors due to homology between regions. For that reason, we tested two different aligners (SOAP and Mosaik), which allow the possibility of maintaining this kind of sequences. We finally decided to use SOAP v1.0 because its output file kept all the information of the input data, while being able to detect SNPs and short (gaps > 1 bp) indel variants in single-end data.

The two high throughput sequencing-based mutation-detection studies published in the literature used MAQ software for SNP-calling [11,18]. In the first study, mutation detection was performed comparing data from tumour and skin tissues from a single leukaemia patient (AML [MIM 601626][11]). The analysis pipeline showed a high false positive rate (87.4%) when trying to confirm final candidate SNPs. This high false positive rate suggested that more stringent conditions were necessary to filter the variants. For that reason, we designed two scores based on intrinsic variant features such as base quality (QS) and depth (DS), which were used as a first filter in our SOAP-based SNP-caller. Although more than 99% of the variants were discarded with this filter, the number of remaining variants suggested the need for further refinement. For that reason, we developed a comparison-based pipeline as previously described (see Material and Methods: Data analysis and Figure 1). Only 1 SNP (less than 1.5% of the variants detected in each individual, and around 6% of the variants shared by the same family) per family on average passed this filtering process, showing that, even after using restrictive thresholds, additional information has to be used to select the most probable variants (Table 5). Candidate SNPs were Sanger sequencing validated, and finally 8 of the 9 SNPs (89%) were confirmed. These variants had a minimum depth of 19× and a maximum depth of 155×, of which between 9 and 70 reads carried the variant. Quality scores were all close to 100, corroborating Solexa’s good base-call quality in those positions.

The 8 variants, which are currently under study (including functional characterization), are located in different genes (Table 6) and could be considered as the final candidate SNPs. The confirmation rate (0.89) and the lack of putatively causal mutations wrongly discarded in the filtering process (Table S2) suggested that our restrictive analysis pipeline successfully identified real previously undescribed variants.

In the second mutational screening study performed using high-throughput technology and MAQ software, the authors set up a global exome-capture method based on microarrays and a specific analysis pipeline, which was conceptually quite similar to ours, to identify causal variants for a monogenic disease [18]. The analysis pipeline was based on comparisons between data from affected individuals, HapMap individuals, and the dbSNP database, considering as candidates those functional variants that were not present in HapMap sample data nor in the dbSNP database. With a subset of our data, we performed a test using MAQ software and our analysis pipeline and observed no correlation between MAQ variant score and the confirmation rate (Table 4), evidencing a lack of accuracy in MAQ’s algorithm.

Regarding indel variants, no indel fulfilled the criteria to be considered a candidate variant, neither in our dataset (Table S1) nor in the previously cited study. This could be due to the fact that indel discovery on single-end data is not as accurate as with the new paired-end technology, affecting the sensitivity of indel detection in both studies. Similarly, we cannot discard the possibility of missing the existence of large rearrangements due to the limitations of single-end data. Recently published studies are starting to demonstrate the efficiency of paired-end sequencing in the identification of genomic rearrangements [19,20].

In another study, a complete mutational screening using Sanger sequencing was performed on 718 genes located on chromosome X in probands from a set of 208 families diagnosed with X-linked mental retardation [21]. The authors obtained 1858 coding variants, among which 1814 (980 missense, 22 nonsense, 13 splice-site, and 799 synonymous) were SNPs, 3 were double SNPs (miscense), and 41 were indels. However, only 18 SNPs (17 nonsense and 1 missense, less than 1% of the initial SNPs) and 15 indels located in 26 different genes resulted to be strong candidates.

Table 4. Variant filtering results using MAQ software.

| Chr | Family | Position (hg18) | Gen | Reference | Variant | MS | Consequence | Sanger confirmation |
|-----|--------|-----------------|-----|-----------|---------|----|-------------|---------------------|
| 3   | 27     | 170968060       | TERC [MIM:602322] | G        | C       | 255/39 | NON_SYNONYMOUS_CODING | No                  |
| 531 |        | 162443032       | NMD3 [MIM:611021] | A        | G       | 16/55  | NON_SYNONYMOUS_CODING | No                  |
| 6   | 531    | 150094561       | NUP43 [MIM:608141] | C        | T       | 38/11  | STOP_GAINED | Yes                 |
| 713 |        | 149763387       | SUMO4 [MIM:608829] | A        | G       | 50/50  | NON_SYNONYMOUS_CODING | No                  |
| 990 |        | 146761618       | GRM1 [MIM:604473] | C        | T       | 93/80  | NON_SYNONYMOUS_CODING | Yes                 |
| 150205485 | | LRP11 | | | | | |
| 151202809 | | PLEKHG1 | | | | |

A lack of correlation between MAQ score (MS) and Sanger sequencing confirmation was observed, since variants showing a MS = 255 (maximum) were not confirmed whereas others with a MS = 55 were validated. MAQ score for individual 1/individual 2.

*variant selected in a non-candidate chromosome for this family because of the truncating effect.

No MIM reference [25].

Recently described in the Ensembl database.

doi:10.1371/journal.pone.0009976.t004
A Novel NGS Analysis Pipeline

Illumina Pipeline Output File
5,137,692 reads*

SOAP alignment
4,819,850 reads aligned against the whole genome*
1,919,870 reads aligned against the candidate regions*

SNP-caller

\[ DS > 50 \quad \text{and} \quad \text{depth} > \bar{MD} \]

SNP variants output file
71 SNPs*

Indel variants output file
1 Indel*

Depth output file

Variants Filtering Process

1. Comparison to control pool data
2. Comparison within the members of the same family
   - Ensembl Database – Perl API tools
3. Non-described variants
4. Removing Intronic consequences
5. Manual No-homology confirmation

Candidate Variants

| SNP variants | Indel variants |
|--------------|---------------|
| 1 SNP***     | 0 Indel***    |

Validation via
Sanger sequencing
99% variants confirmed

Coverage (CGH-like analysis)

1. Division of the candidate coding regions in 15 bp stretches
2. Calculation of the mean and the median of the depth per stretch
3. Normalization of the median
4. Calculation of the log-ratios (Ir) between every affected individual and the control pool:
   \[ Ir = \frac{\bar{MD} - \bar{MD}_c}{\bar{MD}} \]
5. Estimation of the upper and lower threshold per affected individual:
   \[ Ir > \frac{\bar{MD}}{\bar{MD}_c} + 0.5 \quad \text{or} \quad Ir < \frac{\bar{MD}}{\bar{MD}_c} - 0.5 \]
6. Calculation of the correlation between mean and median of the depth in those regions putatively altered

* per individual
** per family
for being involved in X-linked mental retardation. Similarly, our results showed that around 1% of the initial SNP variants obtained via high throughput sequencing could be considered candidates (Table 6). Because no truncating mutations passed our filters, further functional studies are required to assess whether any of the confirmed variants is ultimately a causal mutation, specifically those variants considered of interest because of their functional implications (missense and 3'UTR) and gene function.

In summary, we designed an integral analysis pipeline for mutational screening via SOAP v1.0 that resulted in a low false positive rate with a low probability of discarding real positive variants, with which we identified 8 candidate variants that are currently under functional characterization. We consider that the present strategy might be a valid second step for identifying high penetrance genes, specifically when the regions of interest show significant evidence of linkage.

Materials and Methods

Ethics Statement

All patients provided written informed consent for the collection of samples and subsequent analysis. We obtained ethics approval for this study from the ethics committees at all institutions/hospitals where participants were recruited [17]. The GEO [22] accession number (GSE20406) for this study has been approved as well as GEO accession numbers for each of the samples (Table 7).

Samples and candidate regions

As stated earlier, in a previous study we genotyped a total of 132 individuals from 41 non-BRCA1/2 families with almost 6,000 SNP markers, and we observed a linkage profile showing several candidate regions. Suggestive linkage signals (HLOD >2.2) were found in two regions located on chromosomes 3 and 6, which span 10.8 and 6.5 Mb, respectively, and we found 6 and 5 families putatively linked to each region [17].

In the present study, 10 of these 11 families were selected based on the availability of DNA (from at least 2 affected members per family for a total of 22 DNA samples collected) to perform a mutational screening via massive parallel sequencing. One family (Family 21) was excluded from the final analysis because the DNA library preparation of one of the members failed. However, putatively truncating mutations (e.g. new stop codons or modifications within essential splice sites, and indel variants) were analysed for the remaining individual of this family (see Table S1).

We also sequenced DNA of 4 healthy individuals from Spanish control population, which were pooled into a single control data file. This pooled-control design presented several advantages,

### Table 5. Summary of the variant filtering process.

| Chr | Family | Individual | SNPs | After | Shared by | Undescribed | Consequences | Exonic | Candidate SNPs (%)* |
|-----|--------|------------|------|-------|-----------|-------------|--------------|--------|---------------------|
| 3   | 27     | 075722     | 49   | 10    | 0         | 0           | 0            | 0      | 0 (0.00)            |
|     |        | 075723     | 39   | 2     |           |             |              |        |                     |
|     |        | 075724     | 45   | 18    |           |             |              |        |                     |
|     |        | 075725     | 25   | 4     |           |             |              |        |                     |
| 6   | 60     | 06-240     | 47   | 18    | 15        | 7           | 6            | 3      | 1 (6.67)            |
|     |        | 96-652     | 61   | 26    |           |             |              |        |                     |
|     | 531    | i-1408     | 38   | 15    | 5         | 2           | 1            | 1      | 0 (0.00)            |
|     |        | i-904      | 66   | 42    |           |             |              |        |                     |
| 713 | 075635  | 50         | 32   | 8     | 4         | 5           | 2            | 1      | 1 (12.50)           |
|     | 075636  | 46         | 24   |       |           |             |              |        |                     |
| 6   | 11     | 96.265     | 96   | 36    | 17        | 5           | 12           | 1      | 0 (0.00)            |
|     |        | 04_168     | 81   | 35    |           |             |              |        |                     |
| 40  | 075581  | 93         | 40   | 26    | 8         | 32           | 7            | 3      | 1 (11.54)           |
|     | 075576  | 96         | 53   |       |           |             |              |        |                     |
| 929 | 1-3345  | 81         | 28   | 13    | 3         | 10           | 3            | 0      | 0 (0.00)            |
|     | 1-1627  | 75         | 34   |       |           |             |              |        |                     |
| 990 | 1-1927  | 131        | 63   | 52    | 14        | 40           | 8            | 4      | 1 (7.69)            |
|     | 1-1928  | 119        | 54   |       |           |             |              |        |                     |
| 1125| 1-4347  | 99         | 33   | 11    | 2         | 7            | 0            | 0      | 0 (0.00)            |
|     | 1-2033  | 74         | 26   |       |           |             |              |        |                     |
| **Average** | 71 | 30 | 16 | 5 | 13 | 3 | 1 (6.25) | | |

The number of variants after each of the filtering steps is shown for the 9 non-BRCA1/2 families. The original SNPs were matched against the control pool as well as with the other members of the family. Previously undescribed variants were then selected and consequences obtained using PerlAPI tools. Intronic consequences were discarded and finally the variants were checked for homology.

*with respect to SNPs shared by family.

doi:10.1371/journal.pone.0009976.t005
namely reduced repercussion of differential sample DNA degradation, increased sample heterozygosity, and a balancing effect over the number of reads per sample in the final control data, leading to increased data homogeneity.

**Sequencing and exon-capture**

We used the Illumina single-end technique to perform the sequencing process and an exon-capture protocol recently published [16], which was divided into two steps:

- **a) Library construction.** Genomic DNA (2.5 μg) was fragmented by a triple sonication step. To optimise the sequencing process, we used 5-base barcodes (#1: 5’-GATCT-3’; #2: 5’-ATCGT-3’; #3: 5’-TGTCT-3’; #4: 5’-GTGAT-3’) linked to the ligated oligos, in order to be able to pool 3 or 4 individuals per array and to discriminate the sequences obtained from each individual. After ligating the modified adaptors, 150–300 bp fragments were selected by agarose gel electrophoresis and purified. To obtain a suitable amount of product, multiple parallel PCR reactions were carried out per sample.

- **b) Exon capture.** A total of 142,983 60-mer probes were designed to cover the 787 exonic regions and immobilized on high-density tiling arrays, in order to capture the coding sequences of the 128 genes located in both candidate regions. We used 14 arrays to perform the enrichment step for all the samples. A final amount of 20 μg of PCR product from 3–4 individuals was hybridised onto the array, with several blocking agents, during 65 hours (see Figure 1). After amplification of the eluted DNA, the enrichment was validated by quantitative PCR (qPCR) using the product from 4 different arrays.

**Data analysis**

- **a) Alignment.** After the identification of the sequences belonging to each individual and before the alignment, we removed the first five bases of every sequence corresponding to each of the barcodes. We selected SOAP v1.0 to analyse our dataset using the following parameters: a seed of 12 positions, gaps allowed up to 12 bases, a maximum of 2 mismatches, and a maximum of 5 repeated regions (reporting every region on which the sequences matched equally), using the whole genome as a reference.

| Chr | Position (hg18) | Gene   | Reference | Variant | QS* | DS* | Consequence | Alamuth prediction | Gene function                      |
|-----|----------------|--------|-----------|---------|-----|-----|-------------|-------------------|-----------------------------------|
| 3   | 60             | 161301596 | ACO26118.17* | A       | T   | 91/91 | 96/101     | NCG               | Pseudogene                      |
| 713 | 170284589      | EVI1 [MIM:165215] | A       | G       | 95/94 | 128/100 | 3UTR       | Hematopoietic proliferation protein, related to acute myeloid leukemia |
| 6   | 40             | 152502855 | SYNE1 [MIM:608441] | C       | T   | 105/98 | 90/92      | NSYN              | TOL     | A spectrin repeat containing protein expressed in skeletal and smooth muscle, and in peripheral blood lymphocytes, that localizes to the nuclear membrane |
| 151203125 | PLEKHG1        | C       | T         | 103/98  | 133/146 | SYN      | S1186S | Unknown                      |
| 151713613 | AKAP12 [MIM:604698] | C       | T         | 98/96   | 185/183 | SYN      | P700P | Scaffold protein in signal transduction, is a cell growth-related protein |
| 990 | 146761618      | GRM1    | C       | T       | 101/96 | 101/81 | NSYN      | RS84C AFF | Metabotropic glutamate receptor |
| 150087915 | NUP43          | T       | C         | 95/93   | 101/97 | 3UTR     |       | Part of a nuclear pore complex, mediating bidirectional transport of macromolecules between cytoplasm and nucleus |
| 150205485 | LRP11          | T       | C         | 101/101 | 74/95  | NSYN      | I312V | NDB Unknown                   |
| 151564223 | AL4S1072.14*   | G       | A         | 93/98   | 119/116 | NCG      |       | Non-coding RNA                 |

**Table 6. Final candidate SNPs.**

- a) Quality Score Ind1/Ind2, b) Depth Score Ind1/Ind2, c) NCG: Non-coding gene, SYN: Synonymous, 3UTR: 3’ UTR, NSYN: Non-synonymous.
- d) NDB: Not in database, AFF: predicted to affect the protein, TOL: predicted to be tolerated.
- e) No MIM reference.

Variants confirmed by direct sequencing are marked in **bold**.

- Exon capture. A total of 142,983 60-mer probes were designed to cover the 787 exonic regions and immobilized on high-density tiling arrays, in order to capture the coding sequences of the 128 genes located in both candidate regions. We used 14 arrays to perform the enrichment step for all the samples. A final amount of 20 μg of PCR product from 3–4 individuals was hybridised onto the array, with several blocking agents, during 65 hours (see Figure 1). After amplification of the eluted DNA, the enrichment was validated by quantitative PCR (qPCR) using the product from 4 different arrays.

**Data analysis**

- a) Alignment. After the identification of the sequences belonging to each individual and before the alignment, we removed the first five bases of every sequence corresponding to each of the barcodes. We selected SOAP v1.0 to analyse our dataset using the following parameters: a seed of 12 positions, gaps allowed up to 12 bases, a maximum of 2 mismatches, and a maximum of 5 repeated regions (reporting every region on which the sequences matched equally), using the whole genome as a reference.
reference sequence. One of the main advantages of SOAP v1.0 is its ability to identify short insertions and deletions (indels) in single-end data, while maintaining all input information in the output file. We developed a specific SNP caller written in the Perl programming language to extract the information contained in the SOAP output file. The whole analysis pipeline for re-sequencing data is shown in Figure 1.

b) Coverage. To evaluate the homogeneity of the coverage, we calculated the mean and the median of the depth for stretches of 15 bases along the candidate regions. For each sample, we calculated the mean and the median of the depth for stretches of 15 bases along the candidate regions. For each sample, we obtained the index value (Is) for each 15-base fragment as:

$$Is = \log_2 \frac{MD_{Fs}}{MD_{Fc}}$$

where $MD_{Fs}$ and $MD_{Fc}$ are the median of the depth in a 15-base fragment for the sample and the control pool respectively, and $MD_{s}$ and $MD_{c}$ are the global median of the depth for the sample and the control pool respectively. To select supposedly altered regions, we calculated the upper and the lower thresholds as:

$$Is \geq MD_{s} + 1.5 \times SD_{s} + 0.5$$

or

$$Is \leq MD_{s} - 1.5 \times SD_{s} - 0.5$$

where $MD_{s}$ is the global median and $SD_{s}$ the standard deviation of the depth for the sample. Finally, for these putatively altered regions, we calculated the correlation between the mean and the median of the depth to evaluate possible coverage gaps within them.

c) Scores. To further select candidate heterozygous variants, we calculated the mean quality (base-calling quality from Illumina Genome Analyser) and the allele depth (number of different sequences in which an allele appeared) for both the variant and the reference alleles, and also the global depth (number of different sequences that cover a single base). We calculated two different scores based on the same mathematical formula:

$$score = \left( \frac{X_V}{X_R} \right) \times 100,$$

where $X_V$ represents the mean quality (for Quality Score calculations) or the allele depth (for Depth Score calculations) of the variant allele, and $X_R$ represents in each case the same parameter but for the reference allele. Scores close to 100 indicate that both alleles are equally represented.

In order to determine the optimal DS threshold for the analysis, we performed a study using the information from a single family (Table 3). We used different DS score values for the affected individuals of Family 990 and for the control pool data. We observed that the number of final candidate variants depended mostly on the threshold used for the sample data, although the false positive rate increased when using a DS threshold of 50 for the control data. Taking into account the optimal False Positive/False Negative detection rate and being as conservative as possible, we finally selected a DS threshold of 50 for the samples and a DS threshold of 14 for the control pool data (Table 3).

d) Variants. In the pipeline analysis (Figure 1), firstly those variants with a global depth $< MD_{s}$ and a DS $< 50$ were removed from the sample files as an integral function of the newly-developed SNP-caller. Homozygous variants were also discarded since we expected low-frequency heterozygous variants to be the causal variants. Similarly, variants presenting a DS $< 14$ in the control file were discarded (see above for explanation). Only non-common variants from the previous step were selected for subsequent analysis. The next step was an intrafamilial comparison, with which variants putatively segregating in each family were obtained. Although the filtering process was performed for both SNP and indel variants, from this point onwards subsequent filters were applied to SNP variants only because no indel variants were found that fulfilled the previous conditions (Table S1). We developed a Perl tool to distinguish between described and previously undescribed variants, and also to obtain the consequences of every undescribed variant on the known transcripts, via the Ensembl database through the PerlAPI tools [23]. From this point onwards, intrinsic consequences where filtered out for each affected individual. In order to rule out possible false positives due to homology artefacts, each variant was manually checked for homology using BLAT search [24]. The following step was the confirmation of those variants that passed all filters previously mentioned via Sanger sequencing. As a final step, we used Alamut version 1.5 software to evaluate, in silico, how non-synonymous variants would affect the functionality of the respective candidate proteins (Figure 1).

In order to rule out the possibility that a truncating mutation was detected in one member of a family but not in the others, we analysed the truncating consequences (e.g. stop-gains and alterations in essential splice sites) of the remaining SNPs after comparison against the control pool data (Table S2).
Finally, we compared the sensitivity of our scores with a published reference, and for that we followed our analysis pipeline using MAQ software in a subset of families applying no threshold for MAQ variant score (Table 4).

**Supporting Information**

**Figure S1** Correlations. Coverage along the candidate regions was very high (98% on average) and no correlation between coverage and the number of sequences obtained per individual was observed (A), although we observed a logarithmic trend when the number of sequences aligned to the candidate regions was used (B). On the other hand, a strong correlation between the number of sequences aligned to the candidate coding regions and the mean depth was observed in our dataset (C). Failures in the capture step were discarded since high correlations between the global mean and the global median of the depth per individual (D) and between the mean and the median of the depth in putatively altered 15-bp regions for all the individuals (E) were observed (see text for details).

Found at: doi:10.1371/journal.pone.0009976.s001 (0.13 MB DOCX)

**Table S1** Indel variant filtering process.

Found at: doi:10.1371/journal.pone.0009976.s002 (0.05 MB DOCX)

**Table S2** Putative truncating variants discarded during the filtering process. A. Summary of the whole list of truncating variants (STOP_GAINED and ESSENTIAL_SPLICE_SITE) in some individuals after comparison to the control pool data. The original list has been filtered (Depth Score > 50) for simplicity, given that variants showing a Depth Score below the threshold are likely to be false positives. As evidenced in the table, none of the variants above the threshold has a high Global Depth value, which paired to the fair Depth Score means that in every case the variant allele was detected in a low proportion in relation to the respective reference allele. Additionally, this table shows that no putative candidate truncating variants were discarded during the filtering process, reassuring that filtering using Depth Score and Global Depth is a stringent but adequate filtering step. In conclusion, the low Global Depth and Depth Scores explain why these variants are likely to be false positive results and they were therefore excluded from the final candidate SNP list (Table 6). B. The list of truncating variants for sample 05_980. The other member of this family failed in the library preparation step, but we still performed the analysis of the variants. The most likely variant (in red) was ruled out through Sanger sequencing.

Found at: doi:10.1371/journal.pone.0009976.s003 (0.15 MB DOCX)

**Acknowledgments**

We would like to thank to Ana Osorio and Fernando Fernandez from the Human Genetics Group in the CNIO, and Gordon Assaf from CSHL for their practical and technical support.

**Author Contributions**

Conceived and designed the experiments: JMS GJH JB. Performed the experiments: JMRR EH. Analyzed the data: JMRR FJGA EH GP MR AB LB. Wrote the paper: JMRR FJGA JB.

**References**

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.

2. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7: 552–556.

3. Diez O, Osorio A, Duran M, Martinez-Fernandis JL, de la Hoya M, et al. (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22: 301–312.

4. Bergman A, Abel F, Behboudi A, Yhr M, Mattsson J, et al. (2008) No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p. BMC Med Genet 9: 108.

5. Oldenburg RA, Kraeve-Jansena KH, Hoving-Duistermaat JJ, Bayley JP, Dambrot C, et al. (2008) Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus. Genes Chromosomes Cancer 47: 947–956.

6. Rosa-Rosa JM, Pita G, Urioste M, Llort G, Brunet J, et al. (2009) A 7 Mb region within 11q13 may contain a high penetrance gene for breast cancer. Breast Cancer Res Treat 118: 151–159.

7. Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18: 1851–1858.

8. Li R, Li Y, Kristiansen K, Wang J (2008) SOAP: short oligonucleotide alignment program. Bioinformatics 24: 713–714.

9. Lin H, Zhang Z, Zhang MQ, Ma R, Li M (2008) ZOOM! Zillions of oligos mapped. Bioinformatics 24: 2431–2437.

10. Levy S, Sutton G, Ng PC, Frazer K, Halpern AL, et al. (2007) The diploid genome sequence of an individual human. PLoS Biol 5: e254.

11. Ley S, Mardis ER, Ding L, Fulton B, McLellan MD, et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukemia genome. Nature 456: 66–72.

12. Pushkarev D, Neff NF, Quake SR (2009) Single-molecule sequencing of an individual human genome. Nat Biotechnol.

13. Wang J, Wang W, Li R, Li Y, Tian G, et al. (2008) The diploid genome sequence of an Asian individual. Nature 456: 60–65.

14. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, et al. (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452: 872–876.

15. Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, et al. (2007) Genome-wide in situ exon capture for selective resequencing. Nat Genet 39: 1522–1527.

16. Hodges E, Rocks M, Xuan Z, Bhattacharjee A, Benjamin Gordon D, et al. (2009) Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat Protoc 4: 960–974.

17. Rosa-Rosa JM, Pita G, Urioste M, Llort G, Brunet J, et al. (2009) Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci. Am J Hum Genet 84: 115–122.

18. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, et al. (2009) Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461: 272–276.

19. Leary RJ, Kinde I, Diehl F, Schmidt J, Clouser C, et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Science Translational Medicine Vol 2.

20. Stephens PJ, McBride DJ, Lin ML, Varela I, Ploence ED, et al. (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005–1010.

21. Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, et al. (2009) A genome-wide linkage scan in Dutch hereditary non-polyposis colorectal cancer. Nature 461: 272–276.

22. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, et al. (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452: 872–876.

23. Wang J, Wang W, Li R, Li Y, Tian G, et al. (2008) The diploid genome sequence of an Asian individual. Nature 456: 60–65.